Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population

NCT01337336 · clinicaltrials.gov ↗

COMPLETED

Status

1

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: fluticasone propionate/salmeterol xinafoate
DRUG: Anticholinergics

Sponsor

GlaxoSmithKline